Skip to content
DataLookout
Menu

ZUMA-24NCT05459571

Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Lymphoma

StatusCompleted
PhasePhase 2
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 30 versions: 23 with changes below, 7 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Results posted: Nov 12, 2026 Show 5 more changesShow less
    • Eligibility criteria expanded, about 20 words
    • Primary endpoints: 1 to 2
    • Secondary endpoints: 25 to 32
    • Publications: details revised at 1 of 1 entry
    • Study description shortened, about 1 word
  2. Minor Trial status: Active, Not Recruiting to Completed
    • Enrollment target: estimated 30 to confirmed 35
    • Primary and study completion dates changed from estimate of Dec 2025 to Nov 24, 2025
    v29
  3. Notable Primary completion date: Sep 20, 2024 to Dec 2025
    • Study completion date: Mar 2026 to Dec 2025
    v28
  4. Minor Primary completion date changed from estimate of Mar 2026 to Sep 20, 2024v27
  5. Minor Enrollment target: 35 to 30
    • Secondary endpoints: 24 to 25
    v23
Show 17 earlier versionsHide 17 earlier versions
  1. Minor Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: 30 to 35
    • Study sites: 17 to 16
    v22
  2. Minor Enrollment target: 40 to 30v19
  3. Minor Study sites: 16 to 17v18
  4. Notable Eligibility criteria shortened, about 5 wordsv17
  5. Minor Study sites: 12 to 16v16
  6. Minor Site details revised at 1 of 12 sitesv15
  7. Minor Study sites: 11 to 12v14
  8. Minor Start date: Aug 10, 2022 to Aug 9, 2022v13
  9. Minor Study sites: 10 to 11v12
  10. Minor Study sites: 9 to 10v11
  11. Minor Study sites: 6 to 9v10
  12. Minor Study sites: 5 to 6v9
  13. Minor Study sites revised (5)v7
  14. Minor Study sites: 3 to 5v6
  15. Minor Study sites: 2 to 3v5
  16. Minor Study sites: 1 to 2
    • Start date changed from estimate of Aug 2022 to Aug 10, 2022
    v3
  17. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Percentage of Participants With Treatment-emergent Cytokine Release Syndrome (CRS) as Per Severity
Timeframe: Up to 2.2 years
Percentage of Participants With Treatment-emergent Neurologic Events as Per Severity
Timeframe: Up to 2.2 years

Secondary (32)

Time to Onset of CRS Following Axicabtagene Ciloleucel Administration
Time to Onset of Neurologic Events Following Axicabtagene Ciloleucel Administration
Duration of CRS Following Axicabtagene Ciloleucel Administration
Duration of Neurologic Events Following Axicabtagene Ciloleucel Administration
Percentage of Participants Hospitalized Within 72 Hours of Axicabtagene Ciloleucel Infusion
Show 27 moreShow less
Percentage of Participants Hospitalized Within 4 Days of Axicabtagene Ciloleucel Infusion
Percentage of Participants Hospitalized Within 7 Days of Axicabtagene Ciloleucel Infusion
Percentage of Participants Hospitalized Within 14 Days of Axicabtagene Ciloleucel Infusion
Percentage of Participants Hospitalized Within 30 Days of Axicabtagene Ciloleucel Infusion
Duration of Initial Hospitalization After Axicabtagene Ciloleucel Infusion
Percentage of Intensive Care Unit (ICU) Admitted Participants
Duration of ICU Admission During First Hospitalization After Axicabtagene Ciloleucel Infusion
Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)
Percentage of Participants Experiencing Treatment-Emergent Serious Adverse Events (TESAEs)
Number of Participants With European Quality of Life Five Dimensions Five Levels Scale (EQ-5D-5L) Score
EQ-5D-5L Visual Analogue Scale (EQ-VAS) Score
Percentage of Participants With Objective Response (OR) According to Investigator Assessment Per Lugano Response Criteria for Malignant Lymphoma
Percentage of Participants With Complete Response (CR) According to Investigator Assessment Per Lugano Response Criteria for Malignant Lymphoma
Duration of Response (DOR) According to Investigator Assessment Per Lugano Response Criteria for Malignant Lymphoma
Progression-free Survival (PFS) According to Investigator Assessment Per Lugano Response Criteria for Malignant Lymphoma
Event Free Survival (EFS) According to Investigator Assessment Per Lugano Response Criteria for Malignant Lymphoma
Overall Survival (OS)
Peak Serum Levels of Homeostatic/Proliferative Cytokines: Interleukin (IL)-2, IL-7, and IL-15
Peak Serum Levels of Inflammatory and Immune Modulating Cytokines: Interferon Gamma (IFN-γ), IL-1, IL-6, IL- 13, IL-17, IL-1RA, Granulocyte-macrophage Colony Stimulating Factor (GM-CSF), Tumor Necrosis Factor-Alpha (TNF-α), IL-12p40, and IL-12p70
Peak Serum Levels of Immune Effector Molecules: Granzyme A and Granzyme B
Peak Serum Levels of Immune Effector Molecules: Perforin
Peak Serum Levels of Acute Phase Response Proteins: Serum Amyloid A (SAA)
Peak Serum Levels of the Acute Phase Response Proteins: C-Reactive Protein (CRP)
Peak Serum Levels of the Acute Phase Response Proteins: Ferritin
Peak Serum Levels of the Immune Activation Marker: Soluble IL-2 Receptor Alpha (sIL-2Rα)
Peak Serum Levels of Chemokines: IL-8, C-X-C Motif Chemokine Ligand-10 (CXCL-10), and Monocyte Chemotactic Protein-1 (MCP-1)
Peak Blood Levels of Axicabtagene Ciloleucel Chimeric Antigen Receptor (CAR) T-cells

Arms and interventions

Axicabtagene CiloleucelExperimental

Participants will receive lymphodepleting chemotherapy (cyclophosphamide 500 mg/m\^2/day and fludarabine 30 mg/m\^2/day) over 3 days (Days -5, -4, and -3) followed by prophylactic corticosteroid treatment with 10 mg dexamethasone on Day 0 (prior to axicabtagene ciloleucel), Day 1, and Day 2. Participants will receive axicabtagene ciloleucel consisting of a single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells on Day 0 (following dexamethasone 10 mg) at a target dose of 2 x 10\^6 cells/kg.

Biologicals: Axicabtagene Ciloleucel

Drugs: Cyclophosphamide, Fludarabine, Dexamethasone

Sites

16 sites in 1 country